Project Details
Description
Phase III Randomized Controlled Study Comparing Survival of Patients w/Unresectable Hepatocellular Carcinoma (HCC) Treated w/Thymitaq to Patients Treated with Doxorubicin
| Status | Finished |
|---|---|
| Effective start/end date | 8/24/01 → 8/23/09 |
Funding
- EXIMIAS PHARM CORP
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.